A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Estado	**Tipo de Participantes**	**Rangos de Edad**
Fin Reclutamiento	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase III	54
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	No
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	tratamiento, seguridad, eficacia, farmacocinética	NO

Información

Identificador
2023-503469-49-00 (CTIS)

Cod. Protocolo
54179060CLL3011

Transicionado 2017-004699-77

Área terapéutica
Enfermedades [C] - Cáncer [C04]|

Enfermedad investigada
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Título Científico
A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic

Lymphoma (SLL)

Justificación

No aportado

Objetivo Principal

To assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC)

Variables de Evaluación Primaria

Progression-free survival (PFS) as assessed by an Independent Review Committee (IRC)

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

No aportado

Variables de Evaluación Secundaria

No aportado

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Adult subjects who are: a. 65 years old or, b. 18 to 64 years old and have at least 1 of the following: - Cumulative Illness Rating Scale (CIRS) score >6 - Creatinine clearance (CrCl) estimated <70 mL/min using Cockcroft-Gault equation Diagnosis of CLL or SLL that meets iwCLL criteria Active CLL/SLL requiring treatment per the iwCLL criteria: a. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia or thrombocytopenia or both; b. Massive (ie, at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly; c. Massive nodes (ie, at least 10 cm in longest diameter) or progressive or symptomatic

lymphadenopathy; d. Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time of less than six months; e. Constitutional symptoms, defined as 1 or more of the following: - Unintentional weight loss 10% within the previous 6 months prior to the start of screening; - Significant fatigue (inability to work or perform usual activities); - Fevers higher than 100.5°F or 38.0°C for 2 or more weeks without evidence of infection; - Night sweats for more than 1 month without evidence of infection Measurable nodal disease (by computed tomography [CT]), defined as at least one lymph node >1.5 cm in longest diameter ECOG Performance Status Grade 2 Adequate organ function defined as follows: a. Absolute neutrophil count (ANC) 750 cells/L independent of growth factor support; b. Platelets 50,000 cells/L independent of transfusion support for at least 7 days prior to randomization; c. Hemoglobin >8.0 g/dL independent of transfusion support for at least 7 days prior to randomization; d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3.0 x upper limit of normal (ULN); e. Total bilirubin 1.5 x ULN (unless due to Gilbert's syndrome); f. Estimated CrCl 30 mL/min (Cockcroft-Gault equation)

Criterios de Exclusión

Prior anti-leukemic therapy for CLL or SLL Received live, attenuated vaccine within 4 weeks of randomization History of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic condition that in the opinion of the investigator would adversely affect a subject's participation in the study Currently active, clinically significant Child-Pugh Class B or C hepatic impairment according to the Child Pugh classification Uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk Inability or difficulty swallowing capsules/tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function Presence of del17p or known TP53 mutation detected at a threshold of >10% variable allele frequency (VAF) Major surgery within 4 weeks of first dose of study treatment Known bleeding disorders (eg, von Willebrand's disease or hemophilia) Central nervous system (CNS) involvement or suspected Richter's syndrome An individual organ/system impairment score of 4 as assessed by CIRS, except for the eyes, ears, nose, throat, and larynx system, limiting the ability to receive treatment in this study Uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia (Coombs positivity in the absence of hemolysis is not an exclusion) Chronic use of corticosteroids more than 20 mg/day of prednisone or its equivalent within 7 days of initiation of study treatment History of prior malignancy, except: a. Malignancy treated with curative intent and with no known active disease present for 24 months before randomization; b. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; c. Adequately treated cervical carcinoma in situ without evidence of disease; d. Malignancy, which is considered cured with minimal risk of recurrence

Calendario

(Última actualización: 15/09/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
29/03/2018	17/04/2018	19/04/2018	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
16/01/2019	No aportado	No aportado	No aportado	No aportado

Promotor

Janssen - Cilag International Belgium

Turnhoutseweg 30

Contact Person

CTIS Point of Contact

+31717996133

CTISadmin@its.jnj.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm de la Comunidad Foral de Navarra

C/ Irunlarrea, 3 31008 Pamplona

ceic@cfnavarra.es

Centros

Cerrado (19/06/2019)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Servicio de Hematología

Cerrado (25/11/2022)

Hospital Clínic de Barcelona

Barcelona

BARCELONA

Servicio de Hematología

Activo (28/11/2018)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

No iniciado (--/--/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Hematology

No iniciado (--/--/----)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology

Activo (04/06/2018)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN

Madrid

MADRID

Hematología

Activo (18/06/2018)

HOSPITAL RAMÓN Y CAJAL

Madrid

MADRID

Hematología

Cerrado (24/01/2022)

Hospital Universitari Vall d'Hebron

Barcelona

BARCELONA

Servicio de Hematología

Activo (25/05/2018)

HOSPITAL UNIVERSITARIO DE LA PRINCESA

Madrid

MADRID

Servicio de Hematología

No iniciado (--/--/----)

Hospital Universitario De La Princesa

Madrid

MADRID

Hematology

Cerrado (28/06/2019)

HOSPITAL UNIVERSITARIO DE SALAMANCA

Salamanca

SALAMANCA

Servicio de Hematología

Cerrado (07/08/2019)

HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ

Madrid

MADRID

Servicio de Hematología

Activo (07/05/2018)

HOSPITAL UNIVERSITARIO INFANTA LEONOR

Madrid

MADRID

Servicio de Hermatología

No iniciado (--/--/----)

Hospital Universitario Infanta Leonor

Madrid

MADRID

Hematology

No iniciado (--/--/----)

Hospital Universitario Ramon Y Cajal

Madrid

MADRID

UTMO (Unidad de trasplante de médula ósea)

Cerrado (08/09/2026)

HOSPITAL VIRGEN DEL ROCÍO

Sevilla

SEVILLA

Servicio de Hematología

No iniciado (--/--/----)

University Hospital Virgen Del Rocio S.L.

Sevilla

SEVILLA

Unidad de Ensayos Clínicos, Edificio de laboratorios

Medicamentos

Ibrutinib - capsule - 140 mg
CAPSULE
ORAL USE

-

Principios Activos: N/A

Experimental

Sin resultados

A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

State	Type of participants	Age Ranges
End of recruitment	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase III	54
Results	**Low level of intervention**	**Rare disease**
No results	No	No
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	treatment, safety, effectiveness, pharmacokinetics	NO

Information

Identifier
2023-503469-49-00 (CTIS)

Protocol Code
54179060CLL3011

Transitioned 2017-004699-77

Therapeutic area
Diseases [C] - Cancer [C04]|

Investigated Disease
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Scientific Title
A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic

Lymphoma (SLL)

Rationale

Not provided

Main Objective

To assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC)

Primary Endpoints

Progression-free survival (PFS) as assessed by an Independent Review Committee (IRC)

Temporary moments of secondary assessment

Not provided

Secondary Objective

Not provided

Secondary Endpoints

Not provided

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Adult subjects who are: a. 65 years old or, b. 18 to 64 years old and have at least 1 of the following: - Cumulative Illness Rating Scale (CIRS) score >6 - Creatinine clearance (CrCl) estimated <70 mL/min using Cockcroft-Gault equation Diagnosis of CLL or SLL that meets iwCLL criteria Active CLL/SLL requiring treatment per the iwCLL criteria: a. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia or thrombocytopenia or both; b. Massive (ie, at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly; c. Massive nodes (ie, at least 10 cm in longest diameter) or progressive or symptomatic

lymphadenopathy; d. Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time of less than six months; e. Constitutional symptoms, defined as 1 or more of the following: - Unintentional weight loss 10% within the previous 6 months prior to the start of screening; - Significant fatigue (inability to work or perform usual activities); - Fevers higher than 100.5°F or 38.0°C for 2 or more weeks without evidence of infection; - Night sweats for more than 1 month without evidence of infection Measurable nodal disease (by computed tomography [CT]), defined as at least one lymph node >1.5 cm in longest diameter ECOG Performance Status Grade 2 Adequate organ function defined as follows: a. Absolute neutrophil count (ANC) 750 cells/L independent of growth factor support; b. Platelets 50,000 cells/L independent of transfusion support for at least 7 days prior to randomization; c. Hemoglobin >8.0 g/dL independent of transfusion support for at least 7 days prior to randomization; d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3.0 x upper limit of normal (ULN); e. Total bilirubin 1.5 x ULN (unless due to Gilbert's syndrome); f. Estimated CrCl 30 mL/min (Cockcroft-Gault equation)

Exclusion criteria

Prior anti-leukemic therapy for CLL or SLL Received live, attenuated vaccine within 4 weeks of randomization History of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic condition that in the opinion of the investigator would adversely affect a subject's participation in the study Currently active, clinically significant Child-Pugh Class B or C hepatic impairment according to the Child Pugh classification Uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk Inability or difficulty swallowing capsules/tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function Presence of del17p or known TP53 mutation detected at a threshold of >10% variable allele frequency (VAF) Major surgery within 4 weeks of first dose of study treatment Known bleeding disorders (eg, von Willebrand's disease or hemophilia) Central nervous system (CNS) involvement or suspected Richter's syndrome An individual organ/system impairment score of 4 as assessed by CIRS, except for the eyes, ears, nose, throat, and larynx system, limiting the ability to receive treatment in this study Uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia (Coombs positivity in the absence of hemolysis is not an exclusion) Chronic use of corticosteroids more than 20 mg/day of prednisone or its equivalent within 7 days of initiation of study treatment History of prior malignancy, except: a. Malignancy treated with curative intent and with no known active disease present for 24 months before randomization; b. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; c. Adequately treated cervical carcinoma in situ without evidence of disease; d. Malignancy, which is considered cured with minimal risk of recurrence

Calendar

(Last Update: 15/09/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
29/03/2018	17/04/2018	19/04/2018	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
16/01/2019	Not aported	Not aported	Not aported	Not aported

Sponsor

Janssen - Cilag International Belgium

Turnhoutseweg 30

Contact Person

CTIS Point of Contact

+31717996133

CTISadmin@its.jnj.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm de la Comunidad Foral de Navarra

C/ Irunlarrea, 3 31008 Pamplona

ceic@cfnavarra.es

Sites

Closed (19/06/2019)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Servicio de Hematología

Closed (25/11/2022)

Hospital Clínic de Barcelona

Barcelona

BARCELONA

Servicio de Hematología

Active (28/11/2018)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

not initialized (--/--/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Hematology

not initialized (--/--/----)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology

Active (04/06/2018)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN

Madrid

MADRID

Hematología

Active (18/06/2018)

HOSPITAL RAMÓN Y CAJAL

Madrid

MADRID

Hematología

Closed (24/01/2022)

Hospital Universitari Vall d'Hebron

Barcelona

BARCELONA

Servicio de Hematología

Active (25/05/2018)

HOSPITAL UNIVERSITARIO DE LA PRINCESA

Madrid

MADRID

Servicio de Hematología

not initialized (--/--/----)

Hospital Universitario De La Princesa

Madrid

MADRID

Hematology

Closed (28/06/2019)

HOSPITAL UNIVERSITARIO DE SALAMANCA

Salamanca

SALAMANCA

Servicio de Hematología

Closed (07/08/2019)

HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ

Madrid

MADRID

Servicio de Hematología

Active (07/05/2018)

HOSPITAL UNIVERSITARIO INFANTA LEONOR

Madrid

MADRID

Servicio de Hermatología

not initialized (--/--/----)

Hospital Universitario Infanta Leonor

Madrid

MADRID

Hematology

not initialized (--/--/----)

Hospital Universitario Ramon Y Cajal

Madrid

MADRID

UTMO (Unidad de trasplante de médula ósea)

Closed (08/09/2026)

HOSPITAL VIRGEN DEL ROCÍO

Sevilla

SEVILLA

Servicio de Hematología

not initialized (--/--/----)

University Hospital Virgen Del Rocio S.L.

Sevilla

SEVILLA

Unidad de Ensayos Clínicos, Edificio de laboratorios

Medication

Ibrutinib - capsule - 140 mg

CAPSULE

ORAL USE

-

Active Principles: N/A

Experimental

No results